Literature DB >> 30838474

Acute and chronic remote ischemic conditioning attenuate septic cardiomyopathy, improve cardiac output, protect systemic organs, and improve mortality in a lipopolysaccharide-induced sepsis model.

Takashi Honda1, Quan He1, Fangfei Wang1, Andrew N Redington2.   

Abstract

Remote ischemic conditioning (RIC) is acutely cardioprotective in ischemia-reperfusion injury. We aimed to evaluate the effect of RIC on septic cardiomyopathy and associated multi-organ failure in a lipopolysaccharide (LPS)-induced sepsis mouse model. Balb/c mice were divided into sham, LPS, and LPS + RIC groups. LPS 10 mg/kg or saline control was injected intraperitoneally. RIC was performed by four cycles of 5 min ischemia and 5 min reperfusion of the left lower limb just before the LPS injection. Cardiac function on echocardiography, circulating mediators, blood biochemistry, and MAPK signalling was assessed. Survival 7 days after LPS injection was evaluated in sham-treated, RIC, and daily repeated RIC groups. An LPS-induced decrease in cardiac output was ameliorated by RIC with preserved left ventricular systolic function. LPS-induced increases in TNF-α, IL-1β, IL-6, and high-mobility group box 1 protein (HMGB1) were significantly suppressed by RIC. RIC also suppressed increases in plasma cardiac troponin I, aspartate transaminase, alanine transaminase, blood urea nitrogen, and creatinine with suppressed ERK and JNK phosphorylation in heart, liver, and kidney tissue. RIC significantly improved survival rate (p = 0.0037). Survival rate in the daily repeated RIC group was 100%, and it was higher than that in the RIC group (p = 0.0088). In summary, RIC reduced circulating and myocardial inflammatory mediators associated with septic cardiomyopathy, and led to improved ventricular function, cardiac output, and survival. Our data also revealed that chronic RIC has additional benefit in terms of mortality in sepsis. While further studies are required, RIC may be a clinically useful tool to ameliorate sepsis-induced cardiomyopathy.

Entities:  

Keywords:  High-mobility group box 1 protein; Multiple organ failure; Remote ischemic conditioningm; Sepsis; Septic cardiomyopathy

Mesh:

Substances:

Year:  2019        PMID: 30838474     DOI: 10.1007/s00395-019-0724-3

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  28 in total

Review 1.  Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop.

Authors:  R M Bell; M Basalay; H E Bøtker; S Beikoghli Kalkhoran; R D Carr; J Cunningham; S M Davidson; T J England; S Giesz; A K Ghosh; P Golforoush; A V Gourine; D J Hausenloy; G Heusch; B Ibanez; P Kleinbongard; S Lecour; K Lukhna; M Ntsekhe; M Ovize; A D Salama; G Vilahur; J M Walker; D M Yellon
Journal:  Basic Res Cardiol       Date:  2022-08-15       Impact factor: 12.416

2.  Remote ischemic conditioning in septic shock: the RECO-Sepsis randomized clinical trial.

Authors:  Martin Cour; Kada Klouche; Bertrand Souweine; Jean-Pierre Quenot; Carole Schwebel; Sophie Perinel; Camille Amaz; Marielle Buisson; Michel Ovize; Nathan Mewton; Laurent Argaud
Journal:  Intensive Care Med       Date:  2022-09-14       Impact factor: 41.787

3.  Electroacupuncture pre-treatment alleviates sepsis-induced cardiac inflammation and dysfunction by inhibiting the calpain-2/STAT3 pathway.

Authors:  Xuqing Li; Li Wang; Xinwang Ying; Yujun Zheng; Qianqian Tan; Xiaolan Yu; Jiahong Gong; Ming Li; Xiaofeng Deng; Guanhu Yang; Shengcun Li; Songhe Jiang
Journal:  Front Physiol       Date:  2022-09-07       Impact factor: 4.755

4.  Clinical outcomes of severe sepsis and septic shock patients with left ventricular dysfunction undergoing continuous renal replacement therapy.

Authors:  Guangwei Yu; Kun Cheng; Qing Liu; Wenwei Wu; Huashan Hong; Xiaohong Lin
Journal:  Sci Rep       Date:  2022-06-07       Impact factor: 4.996

Review 5.  FUN14 Domain Containing 1 (FUNDC1): A Promising Mitophagy Receptor Regulating Mitochondrial Homeostasis in Cardiovascular Diseases.

Authors:  Yu Mao; Jun Ren; Lifang Yang
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

6.  Thioredoxin-Interacting Protein (TXNIP) Knockdown Protects against Sepsis-Induced Brain Injury and Cognitive Decline in Mice by Suppressing Oxidative Stress and Neuroinflammation.

Authors:  Yu Zhang; Cheng-Jun Xing; Xiao Liu; Ya-Hong Li; Jing Jia; Jian-Guo Feng; Cheng-Jie Yang; Ye Chen; Jun Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-05       Impact factor: 7.310

7.  MCUb Induction Protects the Heart From Postischemic Remodeling.

Authors:  Jiuzhou Huo; Shan Lu; Jennifer Q Kwong; Michael J Bround; Kelly M Grimes; Michelle A Sargent; Milton E Brown; Michael E Davis; Donald M Bers; Jeffery D Molkentin
Journal:  Circ Res       Date:  2020-04-17       Impact factor: 17.367

8.  Chronic remote ischemic conditioning for cardiovascular protection.

Authors:  Jun Chong; Heerajnarain Bulluck; Andrew Fw Ho; William A Boisvert; Derek J Hausenloy
Journal:  Cond Med       Date:  2019-08

9.  Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer.

Authors:  Muzna Hussain; Yuan Hou; Chris Watson; Rohit Moudgil; Chirag Shah; Jame Abraham; G Thomas Budd; W H Wilson Tang; J Emanuel Finet; Karen James; Jerry D Estep; Bo Xu; Bo Hu; Paul Cremer; Christine Jellis; Richard A Grimm; Neil Greenberg; Zoran B Popovic; Leslie Cho; Milind Y Desai; Steven E Nissen; Samir R Kapadia; Lars G Svensson; Brian P Griffin; Feixiong Cheng; Patrick Collier
Journal:  Am J Cardiol       Date:  2020-09-28       Impact factor: 2.778

10.  RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19.

Authors:  Sean M Davidson; Kishal Lukhna; Diana A Gorog; Alan D Salama; Alejandro Rosell Castillo; Sara Giesz; Pelin Golforoush; Siavash Beikoghli Kalkhoran; Sandrine Lecour; Aqeela Imamdin; Helison R P do Carmo; Ticiane Gonçalez Bovi; Mauricio W Perroud; Mpiko Ntsekhe; Andrei C Sposito; Derek M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-25       Impact factor: 3.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.